Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Pfizer Community
NYSE:PFE Community
4
Narratives
written by author
1
Comments
on narratives written by author
758
Fair Values set
on narratives written by author
Create a narrative
Pfizer
Popular
Undervalued
Overvalued
Community Investing Ideas
Pfizer
FR
Francisco
Community Contributor
Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency
I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines.
View narrative
US$30.62
FV
23.4% undervalued
intrinsic discount
11.82%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
22
users have followed this narrative
2 months ago
author updated this narrative
Pfizer
AN
AnalystHighTarget
Consensus Narrative from 23 Analysts
Next-Gen Biologics And AI Will Tap Global Aging Trends
Key Takeaways A robust late-stage pipeline, strategic acquisitions, and innovation in biologics and AI-driven R&D position Pfizer for long-term growth in key therapeutic areas. Enhanced global market access and operational efficiencies, including cost savings and digital transformation, are expanding Pfizer's revenue base and improving profitability.
View narrative
US$38.61
FV
39.3% undervalued
intrinsic discount
1.59%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
19
users have followed this narrative
1 day ago
author updated this narrative
Pfizer
AN
AnalystConsensusTarget
Consensus Narrative from 23 Analysts
R&D And Oncology Programs Will Shape Future Success
Key Takeaways Focus on R&D productivity and strategic investments is expected to boost future revenue and profitability through potential blockbuster drugs and improved net margins. Cost-saving measures and strategic business investments aim to enhance earnings, supporting EPS growth despite challenges from loss of exclusivity events.
View narrative
US$29.25
FV
19.8% undervalued
intrinsic discount
-1.08%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
405
users have followed this narrative
1 day ago
author updated this narrative
Pfizer
AN
AnalystLowTarget
Consensus Narrative from 23 Analysts
Paxlovid And Vyndaqel Will Fall And Readouts Will Deliver Hope
Key Takeaways Increasing competition and reduced utilization of key drugs could pressure Pfizer's revenue, causing underperformance against market expectations. R&D productivity issues and a streamlined investment focus may limit future revenue growth and impact investor confidence.
View narrative
US$24.57
FV
4.5% undervalued
intrinsic discount
-2.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
29 days ago
author updated this narrative
Your Valuation for
PFE
PFE
Pfizer
Your Fair Value
US$
Current Price
US$23.45
54.2% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-261m
93b
2015
2018
2021
2024
2025
2027
2030
Revenue US$56.2b
Earnings US$7.1b
Advanced
Set Fair Value